Financial Performance - The estimated net profit attributable to shareholders for the first three quarters of 2024 is approximately RMB 1,011.35 billion to RMB 1,087.67 billion, representing a year-on-year increase of about RMB 629.71 billion to RMB 706.03 billion, or a growth of approximately 165% to 185%[2] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is approximately RMB 1,015.16 billion to RMB 1,091.78 billion, with a year-on-year increase of about RMB 632.08 billion to RMB 708.70 billion, also reflecting a growth of approximately 165% to 185%[4] - In the same period of 2023, the total profit was RMB 351.97 billion, and the net profit attributable to shareholders was RMB 381.64 billion[5] Accounting Standards - The company has adopted new accounting standards for insurance contracts and financial instruments starting from January 1, 2024, which may affect the presentation of comparative period information[5] Investment Strategy - The significant increase in investment income is attributed to the recovery of the stock market in the third quarter of 2024, aligning with the company's long-term investment strategy[6] - The company emphasizes the principle of asset-liability matching and has optimized its equity investment structure[6] Performance Forecast - There are no major uncertainties that could affect the accuracy of the performance forecast[7] - The financial data for the first three quarters of 2024 will be detailed in the company's third-quarter report[7] Investor Advisory - Investors are advised to exercise caution when trading the company's shares and to be aware of investment risks[7]
中国人寿(601628) - 2024 Q3 - 季度业绩预告